TROP2-targeting ADCs achieve 50.6% ORR in EGFR-mutant NSCLC following tyrosine kinase inhibitor failure
Antibody-drug conjugates show promise for lung cancer after TKI failure
This systematic review and meta-analysis of 1092 patients found that antibody-drug conjugates (ADCs) provide significant clinical benefits f…
New research highlights how specific antibody-drug conjugates may offer better outcomes for patients with certain types of lung cancer.
Immune microenvironment characterization provides a framework for precision immunotherapy in various thyroid cancer types
New Model Identifies Immune Pathways in Thyroid Cancer Treatment
This systematic review synthesizes the immune evolution of thyroid cancer from autoimmune-driven inflammation to exhausted states in advance…
A new framework maps how immune cells change in thyroid cancer, helping researchers identify better ways to target tumors and overcome treat…
CRT plus EGFR-TKI improves overall survival while EGFR-TKI plus RT ranks first for progression-free survival
Trial Shows Specific Drug Combinations Improve Lung Cancer Survival
This systematic review and network meta-analysis of 1,529 patients with unresectable stage III EGFR-mutated non-small cell lung cancer compa…
New research identifies specific combinations of targeted therapies that may improve survival and manage side effects for certain types of l…
Combination of Local Treatment and Systemic Therapy Improves Outcomes in Patients with Hepatocellular Carcinoma
Combining local and systemic treatments improves survival in liver cancer
This meta-analysis evaluated the addition of local treatments like TACE or HAIC to systemic therapy involving immune checkpoint inhibitors a…
Adding local treatments like TACE or HAIC to immunotherapy can improve response rates and extend survival for patients with hepatocellular c…
Bayesian network meta-analysis of first-line immunotherapy versus TKI for advanced hepatocellular carcinoma
Immunotherapy Outperforms Standard Care for Advanced Liver Cancer
This Bayesian network meta-analysis of 7,301 patients with advanced hepatocellular carcinoma synthesized evidence from randomized trials. It…
A new analysis of 10 clinical trials shows that immunotherapy drugs help people with advanced liver cancer live longer than standard treatme…
Systematic review identifies specific medications significantly associated with drug-induced hyperpigmentation across diverse drug classes
These Common Meds Might Be Darkening Your Skin
A systematic review and meta-analysis evaluated twenty-two studies regarding the incidence of drug-induced hyperpigmentation.
A major review reveals many common medicines can cause noticeable skin darkening.
Concurrent anti-VEGF and anticoagulant use in cancer patients with VTE shows rare bleeding events
Can You Take Blood Thinners With Cancer Drugs Safely?
This retrospective analysis at Hunan Cancer Hospital assessed 208 patients receiving concurrent anti-VEGF agents and anticoagulants for VTE.
New research suggests it is generally safe to use blood thinners with certain cancer treatments.
Triple therapy with TACE, TKIs, and ICIs shows survival benefits in unresectable hepatocellular carcinoma
Triple therapy offers a 52% chance of living three years with advanced liver cancer
This retrospective cohort study evaluated 270 patients with unresectable hepatocellular carcinoma receiving first-line triple therapy across…
Patients with advanced liver cancer receiving triple therapy had a 52% chance of surviving three years, offering new hope for those facing d…
Meta-analysis of TKI combinations in glioblastoma shows improved PFS and ORR with mixed safety signals
New Hope for Glioblastoma Patients Emerges
This meta-analysis evaluated combination treatments incorporating tyrosine kinase inhibitors (TKIs) versus TKI-free control regimens in 1,43…
Imagine getting the hardest diagnosis a person can hear: a fast-growing brain tumor with few good treatment options.
Radical nephrectomy performed for renal inflammatory myofibroblastic tumor in an elderly female
Rare Kidney Tumor Treated Successfully With Surgery Alone
This is a case report of an elderly female patient who underwent radical right nephrectomy for a renal inflammatory myofibroblastic tumor.
A rare kidney tumor was removed with surgery, and no recurrence was seen at 6 months. But this is just one case.
Comprehensive review compares ICI-based regimens and ICI-TKI combinations against sunitinib in metastatic renal cell carcinoma
Kidney Cancer Treatment Just Took a Sharp Turn
This comprehensive review evaluates contemporary immune checkpoint inhibitor (ICI)-based regimens and ICI-tyrosine kinase inhibitor (TKI) co…
New kidney cancer treatments help patients live longer with fewer side effects than older drugs, giving more people a fighting chance agains…
Drug Response Profiling in pediatric ALL yields 68% objective responses and bridges to cellular therapies
Can a simple test find the right drug to save children with tough leukemia?
A prospective, multicenter Drug Response Profiling registry of 340 children with relapsed or refractory acute lymphoblastic leukemia in 17 E…
A simple test matching leukemia drugs to patient cells helped 68% of children respond to treatment and gave 28 of 42 patients a chance to su…
All tyrosine kinase inhibitors Articles
- TROP2-targeting ADCs achieve 50.6% ORR in EGFR-mutant NSCLC following tyrosine kinase inhibitor failure
- Immune microenvironment characterization provides a framework for precision immunotherapy in various thyroid cancer types
- CRT plus EGFR-TKI improves overall survival while EGFR-TKI plus RT ranks first for progression-free survival
- Combination of Local Treatment and Systemic Therapy Improves Outcomes in Patients with Hepatocellular Carcinoma
- Bayesian network meta-analysis of first-line immunotherapy versus TKI for advanced hepatocellular carcinoma
- Concurrent anti-VEGF and anticoagulant use in cancer patients with VTE shows rare bleeding events
- Systematic review identifies specific medications significantly associated with drug-induced hyperpigmentation across diverse drug classes
- Triple therapy with TACE, TKIs, and ICIs shows survival benefits in unresectable hepatocellular carcinoma
- Meta-analysis of TKI combinations in glioblastoma shows improved PFS and ORR with mixed safety signals
- Radical nephrectomy performed for renal inflammatory myofibroblastic tumor in an elderly female
- Comprehensive review compares ICI-based regimens and ICI-TKI combinations against sunitinib in metastatic renal cell carcinoma
- Drug Response Profiling in pediatric ALL yields 68% objective responses and bridges to cellular therapies
- Immune checkpoint inhibitor regimens improve survival versus tyrosine kinase inhibitor monotherapies in advanced hepatocellular carcinoma
- PD-1/PD-L1 inhibitors plus anti-angiogenic TKIs improve PFS but not OS in advanced NSCLC
- In children with Ph+ ALL, TKI-based therapy reduced HSCT use while maintaining comparable outcomes versus Ph+ALL04
- Asciminib superior to IS-TKIs in newly diagnosed CML-CP: MMR 74.1% vs 52.0% at 96 weeks